Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06857955 · ClinicalTrials.gov registry record · Phase 2
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
A Phase 2 study of Hypertension, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 380
- Enrollment target
- 20
- Study locations
NCT06857955 is a Phase 2 study of Hypertension that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 380 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06857955, a Phase 2 study of Hypertension, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 380 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
Conditions Studied
Interventions
- OTHER Saline
- DRUG QCZ484
Study Locations (20)
Florida
- Clinical Research of Brandon LLC - Brandon
- ALL Medical Research LLC - Cooper City
- National Research Institute - Hialeah
- Cen Exel RCA - Hollywood
- East Coast Institute for Research - Jacksonville
- Entrust Clinical Research - Miami
- Inpatient Research Clinical LLC - Miami Lakes
- Inpatient Research Clinical LLC - Miami Lakes
- Suncoast Clinical Research - New Port Richey
California
- NICRs Research Center - Garden Grove
- Valiance Clinical Research - Huntington Park
- Downtown L.A. Research Center Inc - Los Angeles
- Clinical Trials Research Sacramento - Sacramento
- Encompass Clinical Research - Spring Valley
Alabama
- SEC Clinical Research LLC - Andalusia
- UAB St Vincents - Birmingham
- Longwood Research - Huntsville
- The Center for Clinical Trials - Saraland
Arizona
- Elite Clinical Studies - Phoenix
- Synexus Clinical Research US Inc - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2028-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06857955
The ClinicalTrials.gov registry entry for NCT06857955 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (89% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT06857955 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06857955 about?
NCT06857955 is a clinical study titled "A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients". The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
What is the current status of trial NCT06857955?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 380 participants. The study started on 2025-03-26. Estimated completion is 2028-04-05.
What conditions does trial NCT06857955 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT06857955?
The interventions under investigation include: Saline (OTHER), QCZ484 (DRUG).
Who is sponsoring clinical trial NCT06857955?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06857955 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.